Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  recombinant interleukin-3
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 34 for your search:
Start Over
Phase III Randomized Comparison of Low-Dose ARA-C vs ARA-C/GM-CSF vs ARA-C/IL-3 in Patients with High-Risk Myelodysplastic Syndrome
Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 to 80
Sponsor:
Protocol IDs: EORTC-06903
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: NU 97B2, NCI-V00-1611, NCT00006225
Phase II Pilot Study of MDR-1 Retrovirus-Transduced Peripheral Blood Stem Cells for Chemoprotection During Therapy for Advanced Breast Cancer (Summary Last Modified 08/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI
Protocol IDs: MDA-DM-94028, NCI-T95-0064D, T95-0064
Phase II Pilot Study of High-Dose Ifosfamide/Carboplatin/Etoposide (ICE) Followed by Transplantation with neo-r-Transduced Autologous Bone Marrow and PBSC for Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI
Protocol IDs: NCI-92-C-0161I, NCI-MB-294, NCI-T92-0018N, T92-0018
Phase II Study of EPO/IL-3 in Patients with Myelodysplastic Syndrome (Summary Last Modified 05/95)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UARIZ-HSC-91120, NCI-T92-0033D, T92-0033
Phase I Study of IL-3/IL-6 in Patients with Myelodysplastic Syndrome (Summary Last Modified 07/94)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: DFCI-93079, NCI-T93-0001D, T93-0001
Phase I Pilot Study of MDR-1 Retrovirus Transduced Bone Marrow for Chemoprotection During TAX Therapy for Ovarian Cancer (Summary Last Modified 06/95)
Phase: Phase I
Type: Supportive care, Treatment
Status: Closed
Age: 18 to 60
Sponsor: NCI
Protocol IDs: MDA-DM-93012, NCI-T93-0160D, T93-0160
Phase I Study of Recombinant Human IL-3 (SDZ ILE 964) in Patients with Aplastic Anemia and Myelodysplastic Syndromes (Summary Last Modified 04/90)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: MSKCC-89174, NCI-V89-0318
Phase I Study of the Safety and Efficacy of Subcutaneous IL-3 in Patients with Relapsed Ovarian Carcinoma Receiving CBDCA as Second-Line Therapy (Summary Last Modified 06/91)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: CAN-NCIC-IND59, NCI-V91-0001, IND59
Phase I Study of CTX/GM-CSF/IL-3 in Patients with Advanced Cancer (Summary Last Modified 06/91)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRMP-9102, NCI-91-C-113, NCI-T91-0020N, T91-0020
Phase I Study of FLAC (5-FU/CF/DOX/CTX) with GM-CSF plus Escalating Doses of IL-3 in Patients with Breast Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-91-C-121K, NCI-MB-268, NCI-T90-0233N, T90-0233
Phase I Study of IL-3 Administered Prior to and Following CBDCA/VP-16 in Patients with Metastatic Cancer (Summary Last Modified 07/92)
Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: SWOG-9026
Phase I Study of IL-3 with IDA/ARA-C in Adults with Acute Myelogenous Leukemia (Summary Last Modified 04/93)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-DM-91026, NCI-T91-0088D, T91-0088
Phase I Study of High-Dose CBDCA with GM-CSF/IL-3 and PBSC Support in Patients with Advanced Malignancies (Summary Last Modified 04/92)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 16 to physiologic 64
Sponsor: NCI
Protocol IDs: UCSD-90852, NCI-T91-0004D, T91-0004
Phase I Study of IL-3 Following TSPA in Pediatric Patients with Refractory Malignancies (Summary Last Modified 06/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 1 to 24
Sponsor: NCI
Protocol IDs: NCI-91-C-77A, NCI-T90-0216N, T90-0216
Phase IA/IB Study of IL-3 in Patients with Advanced and/or Refractory Cancer (Summary Last Modified 12/92)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: CCF-RPC-3272D, NCI-B90-0021, B90-0021
Phase I Study of DOX/ADR-529/IL-3/GM-CSF in Patients with Advanced Solid Tumors
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYU-9121, NCI-T91-0180D, T91-0180
Phase I Study of IL-3 Followed by CBDCA/CTX/DHAD with Autologous Bone Marrow Transplant and GM-CSF Support for Advanced Malignancies (Summary Last Modified 12/94)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 64
Sponsor: NCI
Protocol IDs: LUMC-T90-0246, NCI-T90-0246O, T90-0246
Start Over